Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Time to target brain atrophy and neurodegeneration in multiple sclerosis.
Defective Autoimmune Regulator-Dependent Central Tolerance to Myelin Protein Zero Is Linked to Autoimmune Peripheral Neuropathy.
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Csf analysis and the diagnosis of neuromyelitis optica.
MRI outcomes in the diagnosis and disease course of multiple sclerosis.
Age-dependent redistribution and hypersialylation of the central myelin paranodal loop membrane protein Opalin in the mouse brain.
No association between body composition and cognition in ambulatory persons with multiple sclerosis: A brief report.
The gut-brain axis: interactions between Helicobacter pylori and enteric and central nervous systems.
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.
Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Erratum.
Detection of demyelination in multiple sclerosis by analysis of [Formula: see text] relaxation at 7 T.
Comparing Three Dual-Task Methods and the Relationship to Physical and Cognitive Impairment in People with Multiple Sclerosis and Controls.
Estrogen treatment of experimental autoimmune encephalomyelitis requires E2 receptor positive B cells that upregulate PD-1 on CD4(+) Foxp3(+) Treg cells.
Autoimmune Hepatitis with Multiple Sclerosis and Graves Disease: Coincidence or Association?
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy.
Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.
7(th) International Immunoglobulin Conference: Interlaken Leadership Awards.
Prostacyclin Prevents Pericyte Loss and Demyelination Induced by Lysophosphatidylcholine in the Central Nervous System.
Antibody biomarkers in CNS demyelinating diseases - a long and winding road.
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis.
Inhibition of phosphoinositide 3-kinase delta attenuates experimental autoimmune encephalomyelitis in mice.
Genomic analysis of ERVWE2 locus in patients with multiple sclerosis: absence of genetic association but potential role of human endogenous retrovirus type W elements in molecular mimicry with myelin antigen.
Olfactory dysfunction in patients with neuromyelitis optica.
Pages
« first
‹ previous
…
641
642
643
644
645
646
647
648
649
…
next ›
last »